首都医科大学附属北京胸科医院
Beijing Chest Hospital
在本站收录的 61 种疾病中,这家医院列在其中 3 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
首都医科大学附属北京胸科医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 肺癌Lung cancer80 篇牵头论文牵头 2 项开放试验
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、胰腺癌、乳腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 80 篇,占 0.3%。
北京有 20 家医院列在肺癌下全国有 251 家医院列在肺癌下
这家医院参与的开放试验 29
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- 分期
- II期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06421298
年龄 18 岁 至 75 岁(登记的条件)
牵头:首都医科大学附属北京胸科医院北京
- 正在招募Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
- 分期
- II期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06467617
年龄 18 岁 至 75 岁(登记的条件)
牵头:首都医科大学附属北京胸科医院北京
- 正在招募Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- 分期
- III期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07195695
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、临沂、北京、南京、南昌、台州、哈尔滨、天津、广州、徐州、成都、扬州、杭州、武汉、济南、石家庄、苏州、郑州、长春、长沙
- 正在招募Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2026-01
- 发布
- 登记号
- NCT07222566
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、太原、广州、成都、扬州、新乡、杭州、武汉、江门、洛阳、济南、温州、福州、襄阳、郑州、重庆、长春、长沙
- 正在招募DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- 分期
- III期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07472517
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、宁波、广州、徐州、成都、扬州、杭州、武汉、济南、温州、福州、蚌埠、襄阳、郑州、长沙
- 正在招募A Study of DS-3939a in Participants With Solid Tumors
- 分期
- I/II期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07739966
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、台州、哈尔滨、天津、广州、杭州、武汉、济南、郑州、长春、长沙
- 正在招募Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- 分期
- II/III期
- 开始
- 2025-01
- 发布
- 登记号
- NCT06712316
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、台州、扬州、杭州、武汉、汕头、济南、石家庄、苏州、蚌埠、重庆、长春、长沙
- 正在招募Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- 分期
- III期
- 开始
- 2025-02
- 发布
- 登记号
- NCT06712355
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南昌、台州、合肥、哈尔滨、太原、广州、扬州、新乡、杭州、武汉、汕头、济南、温州、石家庄、福州、苏州、蚌埠、襄阳、郑州、重庆、长春
- 正在招募This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- 分期
- III期
- 开始
- 2025-07
- 发布
- 登记号
- NCT06758401
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、常州、广州、徐州、成都、杭州、武汉、洛阳、济南、温州、福州、西安、郑州、长沙
- 正在招募Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- 分期
- 未注明
- 开始
- 2025-02
- 发布
- 登记号
- NCT06809764
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 30 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、厦门、合肥、广州、杭州、武汉、沈阳、济南、深圳、石家庄、福州、郑州、青岛
- 正在招募A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- 分期
- II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT06855771
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心临沂、北京、南宁、南昌、厦门、台州、杭州、济南
- 正在招募A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- 分期
- III期
- 开始
- 2025-04
- 发布
- 登记号
- NCT06875310
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、汕头、沈阳、济南、深圳、石家庄、福州、苏州、蚌埠、重庆、长春、长沙
- 正在招募A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- 分期
- II期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06962865
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心临沂、北京、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、武汉、济南、温州、烟台、石家庄、福州、襄阳、郑州、重庆、长春、长沙
- 正在招募A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- 分期
- III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT07010263
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、安阳、广州、新乡、武汉、江门、沈阳、济南、温州、石家庄、福州、西安、遵义、郑州、重庆、银川、长春、长沙
- 正在招募Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- 分期
- I/II期
- 开始
- 2025-07
- 发布
- 登记号
- NCT07079475
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南京、天津、广州、成都、杭州、沈阳、济南、长沙
- 正在招募Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
- 分期
- I/II期
- 开始
- 2025-04
- 发布
- 登记号
- NCT07087223
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学肿瘤医院;另有 7 家列出的医院为研究中心北京、大连、天津、石家庄
- 正在招募A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07182682
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙
- 正在招募Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07185997
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、佛山、北京、南京、南宁、南昌、南通、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、新乡、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、潍坊、石家庄、福州、郑州、重庆、长沙、青岛
- 正在招募A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06203210
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、哈尔滨、天津、成都、杭州、武汉、沈阳、济南、烟台、襄阳、郑州、重庆、长沙
- 正在招募D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- 分期
- III期
- 开始
- 2024-03
- 发布
- 登记号
- NCT06300177
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 63 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、南通、厦门、合肥、哈尔滨、天津、太原、安阳、常州、广州、徐州、成都、新乡、无锡、昆明、杭州、桂林、武汉、沈阳、洛阳、济南、海口、温州、湛江、潍坊、石家庄、福州、西安、遵义、郑州、重庆、长春、长沙
- 正在招募A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06345729
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、无锡、杭州、武汉、济南、温州、福州、苏州、西安、郑州、重庆、长沙
- 正在招募A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- 分期
- II期
- 开始
- 2023-06
- 发布
- 登记号
- NCT05913089
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、天津、太原、潍坊、福州
- 正在招募A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- 分期
- III期
- 开始
- 2023-11
- 发布
- 登记号
- NCT05920356
年龄 18 岁 至 100 岁(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、成都、昆明、杭州、武汉、汕头、洛阳、济南、潍坊、石家庄、福州、蚌埠、襄阳、西安、郑州、重庆、长春、长沙
- 正在招募A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- 分期
- II期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06010329
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南京、南昌、哈尔滨、广州、成都、杭州、武汉、济南、郑州
- 正在招募A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- 分期
- III期
- 开始
- 2022-03
- 发布
- 登记号
- NCT04928846
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙
- 正在招募Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- 分期
- II期
- 开始
- 2022-09
- 发布
- 登记号
- NCT05168566
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、哈尔滨、广州、成都、杭州、武汉、沈阳、蚌埠、郑州、长春、长沙
- 正在招募Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- 分期
- I/II期
- 开始
- 2022-04
- 发布
- 登记号
- NCT05288205
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、临沂、北京、厦门、合肥、呼和浩特、哈尔滨、广州、武汉、沈阳、济南、深圳、福州、郑州、长沙
- 即将招募Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- 分期
- II期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06885840
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心佛山、兰州、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、济南、西安、郑州、长春、长沙
- 即将招募YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- 分期
- III期
- 开始
- 2023-05
- 发布
- 登记号
- NCT05767892
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、呼和浩特、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
医院名称从作者地址自动识别,尚未人工核对。
牵头的论文80
- Superior Performance of Synchronized Percutaneous Microwave Ablation and Immediate Percutaneous Biopsy for Highly Suspected Malignant Pulmonary Ground-Glass Nodules.
- Global patterns and trends in mesothelioma incidence: A retrospective cross-sectional study.
- Multi-omics data-based modeling reveals tumorigenesis- and prognosis-associated genes with clinical potential in lung adenocarcinoma.
- Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China.
- Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.
- Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.
- Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non-Small Cell Lung Cancers.
- Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study.
- Effect of neoadjuvant targeted therapy on the tumor microenvironment in resectable lung adenocarcinoma.
- Two inflammation-related genes model could predict risk in prognosis of patients with lung adenocarcinoma.
- Impact of air pollution on the progress-free survival of non-small cell lung cancer patients with anti-PD-1/PD-L1 immunotherapy: A cohort study.
- Dose-dependent efficacy of CX1003 in NSCLC immunotherapy: High dose for T cell response, low dose for apoptosis.
- Combined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma.
- Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.
- Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study.
- CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients.
- A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small-cell lung cancer.
- Peripheral Immune Cell Profiles as Predictive Biomarkers of Immune Checkpoint Inhibitor Efficacy in Elderly Patients With Advanced Non-Small Cell Lung Cancer.
- Predictive Value of the Estimated Dose of Radiation to Immune Cells Versus Conventional Parameters in Elderly Patients With Unresectable Stage III NSCLC: A Two-Center Real-World Study.
- Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.
- SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes.
- The characteristics and prognoses of 72 postoperative synchronous multiple primary lung cancer patients.
- The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy.
- Identification of JUN gene and cellular microenvironment in response to PD-1 blockade treatment in lung cancer patients via single-cell RNA sequencing.
- Artificial intelligence-driven computer aided diagnosis system provides similar diagnosis value compared with doctors' evaluation in lung cancer screening.
- Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers.
- Value of preoperative evaluation of FEV1 in patients with destroyed lung undergoing pneumonectomy - a 20-year real-world study.
- A case of squamous cell carcinoma of the lung misdiagnosed as tuberculosis. Is HPV infected by oral sex the causative agent?
- Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors.
- T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
- The Ribonuclease ZC3H12A is required for self-inflicted DNA breaks after DNA damage in small cell lung cancer cells.
- Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
- A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
- A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation.
- The prognostic significance of lymph nodes in patients with pT1c33N0M0 non-small cell lung cancer: a retrospective study.
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Associated With Recurrence and Survival of Resectable Non-Small Cell Lung Cancer (NSCLC): A Retrospective Study.
- Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.
- Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer.
- Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
- Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer.
- Chemotherapy for advanced pulmonary sarcomatoid carcinoma: a population-based propensity score matching study.
- High accuracy epidermal growth factor receptor mutation prediction via histopathological deep learning.
- Deep learning-based diagnosis of histopathological patterns for invasive non-mucinous lung adenocarcinoma using semantic segmentation.
- Longitudinal detection of subcategorized CD44v6+ CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center study.
- Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.
- CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
- Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.
- Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network.
- PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer.
- Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex.
- Two germline mutations can serve as genetic susceptibility screening makers for a lung adenocarcinoma family.
- The artificial intelligence and machine learning in lung cancer immunotherapy.
- Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases.
- ASO Author Reflections: A Simple Method to Predict Risk Factors of Complications After Pneumonectomy.
- A Multiple-Center Nomogram to Predict Pneumonectomy Complication Risk for Non-Small Cell Lung Cancer Patients.
- A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
- Identification of serum MiRNAs as candidate biomarkers for non-small cell lung cancer diagnosis.
- Expression and potential role of CCL4 in CD8+T cells in NSCLC.
- Circulating myeloid-derived suppressors cells correlate with clinicopathological characteristics and outcomes undergoing neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
- CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.
- IncRNA Linc00511 Upregulation Elevates TGFBR1 and Participates in the Postoperative Distant Recurrence of Non-Small-Cell Lung Cancer by Targeting miR-98-5p.
- Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
- Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis.
- CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer.
- Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer.
- Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
- Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.
- Long non-coding RNA BZRAP1-AS1 functions in malignancy and prognosis for non-small-cell lung cancer.
- IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer.
- Identification of a competing endogenous RNA axis "SVIL-AS1/miR-103a/ICE1" associated with chemoresistance in lung adenocarcinoma by comprehensive bioinformatics analysis.
- Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
- Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy.
- Associated factors of co-existent pulmonary tuberculosis and lung cancer: A case-control study.
- Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients.
- Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape.
- Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced NSCLC.
- Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.
- Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.
- A Modified Method to Isolate Circulating Tumor Cells and Identify by a Panel of Gene Mutations in Lung Cancer.
- ALK-rearranged squamous cell carcinoma of the lung.
中文论文(未计入)18
- [Analysis of the Correlation between Immune Cell Subsets in Bronchoalveolar Lavage Fluid and the Efficacy of First-line Use of Immunotherapy in Advanced Non-small Cell Lung Cancer: A Case-control Study].
- [Clinicopathological Characteristics and Prognosis Analysis of 39 Patients with Pulmonary Sarcomatoid Carcinoma].
- [Clinical characteristics and prognostic factors of epidermal growth factor receptor-mutated non-small cell lung cancer transformed into small-cell lung cancer after treatment].
- [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
- [Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].
- [Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].
- [Analysis of the Efficacy of Immunotherapy in Elderly Patients with Lung Cancer].
- [Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].
- [Expression of CD44 in Tumor Tissue and Serum of Small Cell Lung Cancer and Its Clinical Prognostic Significance].
- [Analysis of the Efficacy of Immunotherapy on the Posterior Lines of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer].
- [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-small Cell Lung Cancer].
- [Research Progress of Single Cell Sequencing in Lung Cancer].
- [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
- [Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer].
- [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
- [Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases].
- [Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
- [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
它在 ClinicalTrials.gov 上的全部试验(任何状态)96
- Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
- The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)
- Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- A Study of DS-3939a in Participants With Solid Tumors
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
- A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
- Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
- A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
- A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
- A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
- A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
- TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
- A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
- A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
- Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
- A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Lorlatinib Continuation Study
- Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
- A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
- Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
- A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
- Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
- TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
- Cancer Genome Atlas of China:Lung Cancer
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
- A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
- A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
- A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
- A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
- The Tracking Molecular Evolution for NSCLC (T-MENC) Study
- A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
- Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
- Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer
- A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
- A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
- Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)
- A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
- Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer
- High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
- Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
- A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
- Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
- Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer
- A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
- A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
- Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
- Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
- BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
- Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
- Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 23 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
医院名称从作者地址自动识别,尚未人工核对。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 25 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
医院名称从作者地址自动识别,尚未人工核对。
联系这家医院
出示给工作人员或司机的院名卡
首都医科大学附属北京胸科医院
Beijing Chest Hospital
北京
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药